Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Epirus Biopharmaceuticals Inc    EPRSQ

 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Bulletin Board - Othe…
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
0.018(c) 0.013(c) 0.022(c) 0.015(c) 0.016(c) Last
5 199 35 801 110 272 77 107 11 273 Volume
0.00% -27.78% +69.23% -31.82% +6.67% Change
More quotes
Company
EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business.It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference... 
More about the company
Latest news on EPIRUS BIOPHARMACEUTICALS
2016 EPIRUS BIOPHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Co..
2016 EPIRUS BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Te..
2016 EPIRUS BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Ot..
2016 EPIRUS BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial Co..
2016 EPIRUS BIOPHARMACEUTICALS : Announces Reprioritization of Pipeline to Solely Foc..
2016 TUESDAY SECTOR LAGGARDS : Apparel Stores, Biotechnology Stocks
2016 EPIRUS BIOPHARMACEUTICALS, INC. : Costs Associated with Exit or Disposal Activit..
2016 EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars ..
2016 EPIRUS BIOPHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
2016 EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financi..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart EPIRUS BIOPHARMACEUTICALS
Duration : Period :
Epirus Biopharmaceuticals  Technical Analysis Chart | EPRSQ | US29428P1075 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Sector and Competitors
1st jan.Capitalization (M$)
EPIRUS BIOPHARMACEUTIC..-43.86%0
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results